AUTHOR=Morel Alix , Lebard Pierre , Dereux Alexandra , Azuar Julien , Questel Frank , Bellivier Frank , Marie-Claire Cynthia , Fatséas Mélina , Vorspan Florence , Bloch Vanessa 

TITLE=Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers

JOURNAL=Frontiers in Psychiatry

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.565617

DOI=10.3389/fpsyt.2021.565617

ISSN=1664-0640

ABSTRACT=<p><bold>Background:</bold> Cannabidiol (CBD) is a cannabinoid of potential interest for the treatment of substance use disorders. Our aim was to review the outcome measures, surrogate endpoints, and biomarkers in published and ongoing randomized clinical trials.</p><p><bold>Methods:</bold> We conducted a search in PubMed, Web of Science, PMC, PsycINFO, EMBASE, CENTRAL Cochrane Library, “<ext-link ext-link-type="uri" xlink:href="https://clinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicalTrials.gov</ext-link>,” “clinicaltrialsregister.eu,” and “anzctr.org.au” for published and ongoing studies. Inclusion criteria were randomized clinical trials (RCTs) examining the use of CBD alone or in association with other cannabinoids, in all substance use disorders. The included studies were analyzed in detail and their qualities assessed by a standardized tool (CONSORT 2010). A short description of excluded studies, consisting in controlled short-term or single administration in non-treatment-seeking drug users, is provided.</p><p><bold>Findings:</bold> The screening retrieved 207 published studies, including only 3 RCTs in cannabis use disorder. Furthermore, 12 excluded studies in cannabis, tobacco, and opioid use disorders are described.</p><p><bold>Interpretation:</bold> Primary outcomes were validated withdrawal symptoms scales and drug use reduction in the three RCTs. In the short-term or crossover studies, the outcome measures were visual analog scales for subjective states; self-rated scales for withdrawal, craving, anxiety, or psychotomimetic symptoms; and laboratory tasks of drug-induced craving, effort expenditure, attentional bias for substance, impulsivity, or anxiety to serve as surrogate endpoints for treatment efficacy. Of note, ongoing studies are now adding peripheral biomarkers of the endocannabinoid system status to predict treatment response.</p><p><bold>Conclusion:</bold> The outcome measures and biomarkers assessed in the ongoing CBD trials for substance use disorders are improving.</p>